HOME >> BIOLOGY >> NEWS
Maillinckrodt Medical Licenses Invention For Concentration Of Rhenium Radioisotopes

OAK RIDGE, Tenn., Jan. 20, 1997 --Mallinckrodt Medical Inc. has licensed an invention from the Department of Energy's (DOE) Oak Ridge National Laboratory (ORNL) that could save more than 100,000 people from having additional heart surgery.

Of the 400,000 balloon angioplasty procedures that are performed annually in the United States, 30 percent of patients require additional surgery because their arteries clog up again, but the use of a special radioactive isotope -- rhenium-188 -- prevents this arterial blockage from forming.

Rhenium 188 is available from the tungsten-188/rhenium-188 generator developed in the ORNL Nuclear Medicine program.

Although a variety of pharmacological approaches are being explored to inhibit restenosis after balloon angioplasty, ionizing radiation has been found to be one of the only non-surgical and easily performed procedures which is effective. This can be accomplished using the technology developed at ORNL and licensed to Mallinckrodt.

A highly concentrated form of rhenium is needed for this type of procedure and is provided by a special ion exchange system developed at ORNL. The concentration method, developed by researchers at the laboratory, uses rhenium-188 for the radiation of the coronary arteries after angioplasty. Rhenium treatment following balloon angioplasty cuts the rate of restenosis, or reblockage of the arteries, significantly.

The licensing agreement gives the St. Louis-based company sole commercial, field-of-use rights for the invention. With restenosis occurring in 25 percent to 30 percent of angioplasty patients, "the invention will help save time, lives and costs -- for both hospitals and patients," said Russ Knapp, principal investigator who led the team.

The technology was developed at ORNL by Knapp, Arnold Beets, Saed Mirzadeh and Stefan Guhke of the Life Sciences Division. Robert Mills, vice president and general manager of Mallinckrodt Interventional, said that Mallinckrodt
'"/>

Contact: Ron Walli
wallira@ornl.gov
423-576-0226
DOE/Oak Ridge National Laboratory
20-Jan-1998


Page: 1 2

Related biology news :

1. Joslin Diabetes Center adds first affiliate in California at Irvine Medical Center
2. LA BioMed Medical/Research Briefs, July/August 2004
3. Medical implants work better when you rough them up, study finds
4. Dartmouth Medical School awarded $9 million grant for genomics research
5. University of Pittsburgh Medical Center acquires biotechnology firm Rheogene Inc.
6. European Society for Medical Oncology Cancer Conference
7. Medical students inadequately prepared for clinical rotations, caring for chronically ill
8. Harvard Medical School launches new department to study human biology at the level of whole systems
9. Grant strengthens research arm of Penn State Hershey Medical Centers ALS Clinic
10. Univ. of Pittsburgh Medical Center leads group buying PPLS cloning, stem cell business
11. Dartmouth Medical School geneticists discover new role for antisense RNA

Post Your Comments:
(Date:5/21/2013)... new method for delivering molecules into single, targeted ... The technique could find applications in drug delivery, ... electroporation a technique used to deliver molecules ... membrane that are caused by exposing them to ... of cell transfection. (Cell transfection is the introduction ...
(Date:5/21/2013)... available in pharmacies and health stores, phosphatidylserine is ... and soy. Proven to improve cognition and slow ... people experiencing memory impairment. Now a team headed ... of Tel Aviv University,s Department of Human ... supplement improves the functioning of genes involved in ...
(Date:5/21/2013)... Chemical Society (ACS), the world,s largest scientific society, ... Meeting & Exposition, September 8-12, 2013, in Indianapolis, ... Convention Center and at area hotels. , With ... span science,s horizons from astronomy to zoology ... online journalists a rich assortment of spot news ...
Breaking Biology News(10 mins):Single-cell transfection tool enables added control for biological studies 2Common food supplement fights degenerative brain disorders 2
(Date:5/22/2013)... May 22, 2013 Express Diagnostics ... Pty Ltd are pleased to announce a sponsorship ... Australian and New Zealand distributor of DrugCheck® onsite testing ... Team participated in the Austin 400 May 17-19 in ... an agreement that involves each car of the Erebus ...
(Date:5/22/2013)... 22, 2013 Envera announced today that ... Mr. McErlean has an extensive background in cell ... throughout his career. , Mike Matheny, President ... to have Mike join our team”. “Mike’s background is ... fermentation and downstream processing equipment”, added Matheny. ...
(Date:5/22/2013)... 22, 2013 The ability to ... the information they encode. There are now a ... sequencing of ribosome protected fragments) that dramatically expand ... Keynote speakers include Dr. Jonathan Weissman, an Investigator ... Howard Hughes Medical Institute, who will present recent ...
(Date:5/21/2013)... 22, 2013 First patients dosed ... glycopyrronium bromide designed using Prosonix, particle engineering platform ... portfolio of inhaled Respiratory Medicines by Design , ... that will assess its effect on lung function and ... with moderate to severe chronic obstructive pulmonary disease (COPD). ...
Breaking Biology Technology:Australian Distributor of Express Diagnostics Signs Sponsorship Agreement with V8 Supercar Team 2Envera Appoints Michael McErlean Fermentation Manager 2Monitoring Protein Synthesis One Codon at a Time Through Ribosome Profiling, a Webinar Hosted by Xtalks 2Prosonix Initiates Phase 2 Clinical Study with PSX1002 in Patients with Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD) 2Prosonix Initiates Phase 2 Clinical Study with PSX1002 in Patients with Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD) 3Prosonix Initiates Phase 2 Clinical Study with PSX1002 in Patients with Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD) 4
Cached News: